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Abstract 
Tryptophan hydroxylase (TPH) catalyzes the initial and rate-limiting step in the biosynthesis of serotonin, 
which is associated with a variety of disorders such as depression and irritable bowel syndrome. TPH exists 
in two isoforms; TPH1 and TPH2. TPH1 catalyzes the initial step in the synthesis of serotonin in the 
peripheral tissues, while TPH2 catalyzes this step in the brain. In this study, the steady-state kinetic 
mechanism for the catalytic domain of human TPH1 has been determined. Varying substrate tryptophan 
(Trp) and tetrahydrobiopterin (BH4) results in a hybrid Ping Pong-ordered mechanism in which the reaction 
can either occur through a Ping Pong or a sequential mechanism depending on the concentration of 
tryptophan. The catalytic domain of TPH1 shares a sequence identity of 81 % with TPH2. Despite the high 
sequence identity, differences in the kinetic parameters of the isoforms have been identified, i.e. only TPH1 
displays substrate tryptophan inhibition. This study demonstrates that the difference can be traced to an 
active site loop which displays different properties in the TPH isoforms. Steady-state kinetic results of the 
isoforms, and variants with point mutations in a loop lining the active site, show that the kinetic parameters 
of only TPH1 are significantly changed upon mutations. Mutations in the active site loop of TPH1 result in 
an increase in the substrate inhibition constant, Ki, and therefore turnover rate. Molecular dynamics 
simulations reveal that this substrate inhibition mechanism occurs through a closure of the co-substrate, BH4, 
binding pocket, which is induced by Trp binding.  
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Introduction 
Tryptophan hydroxylase (TPH) catalyzes the first and rate-limiting reaction in the biosynthesis of the 
hormone and neurotransmitter serotonin (5-HT). TPH uses Fe2+, tetrahydrobiopterin (BH4), and O2 to 
generate 5-hydroxytryptophan (5-HTP) by hydroxylation of tryptophan (Trp).1 5-HTP is converted to 5-HT 
by aromatic amino acid decarboxylase 2,3. Together with phenylalanine hydroxylase (PAH) and tyrosine 
hydroxylase (TH), TPH is a member of the enzyme subfamily of iron(II)-containing monooxygenases which 
are known as aromatic amino acid hydroxylases (AAAHs). The enzymes in the AAAH family form 
tetramers, in which each monomeric subunit consists of an N-terminal regulatory domain, a highly conserved 
catalytic domain, and a C-terminal tetramerization domain.1,4 In human two isoforms of TPH exist, where 
isoform 1 (TPH1) mainly is responsible for catalyzing the initial step in the biosynthesis of peripheral 
serotonin, and isoform 2 (TPH2) is associated with biosynthesis of neuronal serotonin1. Dysregulation of 
serotonin levels is involved in various physiological and psychiatric disorders such as irritable bowel 
syndrome, depression, obsessive compulsive disorder, and schizophrenia5. Decreased levels of neuronal 
serotonin are associated with neurological disorders, whereas some gastrointestinal disorders are associated 
with increased peripheral serotonin levels6- 8.  
The kinetic mechanism has not unambiguously been determined for the aromatic amino acid hydroxylases. 
Despite great efforts to dissect the mechanism, ambiguities still exist. Of the AAAHs, PAH and TH have 
been more thoroughly studied. Steady-state kinetic studies have shown that bovine TH follows a Ping Pong 
mechanism.9,10 This mechanism is supported by observation that in rat TH, where oxidation of BH4 can 
occur in the absence of substrate tyrosine at pH 8.2.11 However, the oxidation occurs at slower rates at pH 
7.2 and not at all at pH 6.5.11,12 In contrast, another steady-state kinetic study on rat TH finds an ordered 
sequential mechanism involving a quaternary complex with all three substrates bound.12 The presence of a 
ternary complex which binds O2 during catalysis in rat TH, is supported by a spectroscopic study. 13 
Furthermore, a sequential mechanism is supported by single turn-over kinetic studies on PAH from 
chromabacterium violaceum 14 , 15  and rat 16 . Similar results have been obtained for rabbit TPH1. 17  The 
substrate binding order in the AAAHs have been established to occur in an ordered fashion where pterin 
binds followed by substrate amino acid and then O2. 9,15,16 That pterin binds as the first substrate is consistent 
with finding in TPH1 where inhibitors display uncompetitive inhibition towards 6-MePH4, which indicates 
that pterin binds first.18 Additionally, the crystal structure of chicken TPH (pdb: 3E2T) shows that binding of 
tryptophan and possibly imidazole results in a closed conformation, which indicates the formation of a dead-
end complex.19 Despite a sequence identity of 71 %, the two isoforms of TPH display differences in their 
kinetic properties.20, 21 Some of the differences are accounted for by the N-terminal regulatory domains. 
TPH2 has an additional 46 residues in the regulatory domain compared to TPH1. This terminal extension has 
a great impact on enzymatic activity, and serine 19 in the terminus of TPH2 has been identified as a 
phosphorylation site. 22  However, even in the absence of the regulatory domains, the isoforms display 
4 
 
different kinetic properties.21 Besides differences in kinetic parameters (Km and Vmax-values), TPH1 displays 
a greater degree of substrate tryptophan inhibition compared to TPH2.20, 21 Human TPH1 variants without the 
regulatory or tetramerization domain exhibit substrate inhibition comparable to full-length TPH1. 23 The 
underlying molecular mechanism of this inhibition and the differences in the isoforms that govern these 
observations remains elusive.  
Here, we describe results that identify the steady-state kinetic mechanism for the catalytic domain of human 
TPH1. Furthermore, we describe results that identify the structural origin of the competitive substrate 
inhibition mechanism. The inhibition mechanism of TPH1 is governed by the orientation of Tyr125 which 
enables the active site loop to participate in the mechanism. Participation of Tyr125 occurs through the 
adjacent Tyr235 which is found to block the active site access upon substrate Trp binding.  
Experimental Procedures 
Materials. All used chemicals were of analytical grade, and all solutions were prepared using water from an 
18.2 MΩ·cm Milli-Q synthesis A10 Q-Gard system which was filtered through a 0.22 µm filter. Protein 
purification was performed on an ÄKTA purifier 100 from GE Healthcare. Utilized GE Healthcare column 
are: HiLoad Superdex 200 26/60 pg, Superdex 200 10/300 GL, and a XK 16/20 column packed with 25 mL 
Dextrin Sepharose High Performance media. During purifications, all TPH containing solutions were kept in 
ice water, except during the chromatographic steps, which were performed at room temperature. Protein 
solutions were concentrated using an Amicon ultrafiltration cell with an Ultracell PL-3 membrane. Protein 
concentrations were determined by measuring the absorbance at 280 nm on an ND-1000 NanoDrop 
Spectrophotometer from Saveen Werner.  
Cloning and Expression. Full-length human TPH2 cDNA optimized for expression in E. coli was obtained 
from GenScript. The construct encoding the different protein variants was obtained by PCR. All DNA 
sequences were verified by sequencing (Eurofins). All proteins were expressed as maltose binding protein 
fusion proteins from the pET26 expression vector in E. coli BL21(DE3) (Novagen) cells. All TPH1 and 
TPH2 variants were expressed as NΔ99/CΔ31 and NΔ145/CΔ31, respectively, lacking the N-terminal 
regulatory domain and the C-terminal tetramerization domain. The sequences of the proteins expressed are 
given in Supporting Information. The recombinant fusion proteins contain a cleavage recognition site for 
human rhinovirus 3C protease (3CP)24. Proteins were expressed at 20°C for 14 h as previously described25. 
MBP-3CP was cloned, expressed, and purified in-house. 
Purification. The purification procedure comprises an affinity chromatography step utilizing a column 
packed with dextrin sepharose and a size exclusion step using a HiLoad Superdex 200 prep grade column, as 
previously described26. All variants were cleaved from the MBP fusion protein utilizing an on-column 
cleavage procedure with MBP-3CP during the first purification step. Human TPH1 variants were purified in 
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buffer containing 20 mM TRIS/H2SO4, 100 mM (NH4)2SO4, pH 8.0 and human TPH2 variants in 20 mM 
HEPES/NH4OH, 100 mM (NH4)2SO4, pH 7.0. 
Activity Assay. The activity assay was performed as described by Moran et al.27 and Nielsen et al.25, and the 
sample preparation was conducted as previously described26. The activity measurements were performed 
using a Varian Cary Eclipse Fluorescence Spectrophotometer. For activity measurements, the TPH variants 
were thawed under running water, filtered, and the concentrations were determined by UV-Vis absorption at 
280 nm. The TPH samples were diluted with the buffer in which they were purified. TPH activity was 
assayed in a reaction mixture (10x10 mm QS quartz cuvette from Hellma - 2500 µL total volume) containing 
50 mM HEPES/NH4OH, 200 mM (NH4)2SO4, pH 7.0, 0.025 g/L catalase, 25 µM (NH4)2Fe(II)(SO4)2.6H2O, 7 
mM dithiothreitol (DTT) with stirring at 15 °C. The concentration of TPH was 0.8 µM in all measurements 
except for Trp at 1.5 and 2.5 µM, where the concentrations were 0.24 and 0.4 µM, respectively. The standard 
substrate concentrations were 70 µM L-Trp, 300 µM BH4, and 500 µM O2. The O2 concentration was 
achieved by equilibrating the solution with a mixture of O2 and N2 as previously described.25 Excitation and 
emission wavelengths were 300 and 330 nm, respectively. Initial velocity was determined from linear 
regression through the first 0.04 min after BH4 addition. Apparent kinetic parameters were calculated by 
curve fitting using non-linear least-squares approach. When only one substrate was varied, the initial velocity 
data were fitted using eq. 1 or eq. 2 in case of substrate inhibition. When two substrates were varied, the 
initial velocity data were fitted using eq. 3. 28,29,30 
𝑣𝑣𝑖𝑖 = 𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚[𝑆𝑆]𝐾𝐾𝑚𝑚 + [𝑆𝑆]                                                                                                                   (1) 
𝑣𝑣𝑖𝑖 = 𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚[𝑆𝑆]
𝐾𝐾𝑚𝑚 + [𝑆𝑆] + [𝑆𝑆]2𝐾𝐾𝑖𝑖                                                                                                       (2) 
𝑣𝑣𝑖𝑖 = 𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚[𝐴𝐴][𝐵𝐵] + 𝑉𝑉2[𝐴𝐴][𝐵𝐵]2
𝐾𝐾𝑚𝑚,𝐴𝐴[𝐵𝐵] �1 + [𝐵𝐵]𝐾𝐾𝑖𝑖 � + 𝐾𝐾𝑚𝑚,𝐵𝐵[𝐴𝐴] + [𝐴𝐴][𝐵𝐵] + 𝐾𝐾3[𝐵𝐵]2 + 𝐾𝐾4[𝐴𝐴][𝐵𝐵]2                  (3) 
Kinetic parameters were determined from three independent experiments from at least two different 
purifications batches for each variant. 
Molecular Dynamic Simulations. The x-ray structures of TPH1 (pdb: 1MLW, open loop conformation) and 
TPH2 (pdb: 4V06, open loop conformation) were used as initial models for MD simulations. The crystal 
structure of human TPH1 lacks interpretable electron density in the C-terminus (residue 394 to 413). 
Homology modeling was utilized to build the terminus with 4V06 as template. The position and orientation 
of substrate Trp were obtained from the crystal structure of chicken TPH (pdb: 3E2T19) and superimposed 
into the structures of human TPH isoforms. In the Schrödinger suite, mutations were performed by Residue 
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Scanning in the BioLuminate suite.31 The proteins were prepared for simulation with the default parameters 
of the Protein Preparation Workflow in Maestro32. Protonation states at pH 8.0 were assigned with the 
PropKa module33. The system was built by adding 0.3 M NaCl and water molecules (TIP3P model34) in an 
orthorhombic box exceeding 10 Å in each direction from the protein using System Builder workflow in 
Desmond35. The MD simulations were performed with the Desmond package using the OPLS3 force-field36, 
and periodic boundary conditions in all three Cartesian coordinates were applied. Particle-mesh Ewald 
method37 was applied to calculate long-range electrostatic interactions. Short-range electrostatic and van der 
Waals interactions were smoothly truncated at 9 Å. The simulations were run with constant number of 
atoms, with constant temperature of 300 K maintained with Nosé–Hoover thermostats 38 , and constant 
pressure maintained at 1.01325 bar with the Martyna–Tobias–Klein barostat method39. RESPA integrator40, 
with a 2.0-fs time step was utilized to solve the equations of motion for bonded and short-range interactions.  
The RESPA integrator default setting for nonbonded interactions beyond the 0.9-nm cutoff was 6.0-fs time 
step. Before every 100-ns production simulation run, a relaxation with the default parameters in Desmond 
was performed. Configurations and energies were saved at 5-ps intervals. Convergences of the MD 
simulations were based on RMSD calculations. 
Results 
Enzymatic -Mechanism - To explore the kinetic mechanism of TPH1, the initial velocities of the catalytic 
domain of human TPH1 (chTPH1) was determined at various tryptophan and BH4 concentrations. The 
concentrations of the substrates were varied in a concentration matrix of 14 tryptophan concentrations and 
six BH4 concentrations. The O2 concentration was 500 µM in all measurements and apparent kinetic 
parameters were hence derived. This data is presented in Figure 1. For clarity, only the lowest seven 
concentrations of tryptophan are shown in Figure 1B. (For all concentrations see Supporting Information 
Figure S1). Figure 1A shows that the data deviate from the classical hyperbolic curve. The data can be fitted 
very well with the Michaelis-Menten equation with a substrate inhibition term (eq. 2) (see Figure S2), which 
describes linear substrate inhibition resulting from a dead-end complex formation between substrate and a 
non-productive enzyme form.41 When the data in Figure 1A are replotted as v0 versus [BH4], the plots in 
Figure 1B are obtained. The data follow a classic hyperbolic shape, and the Michaelis-Menten equation (eq. 
1) fits well to the data (Figure S3). By fitting eq. 2 to the data for each fixed BH4 concentration, apparent 
tryptophan substrate inhibition constants, Ki, can be determined. The secondary plot in Figure 2 shows that 
chTPH1 displays BH4 concentration-dependent substrate inhibition. For instance, at low fixed concentrations 
of BH4 (20 µM), chTPH1 has an apparent Ki of 24 µM, while at high BH4 concentration (400 µM) the 
apparent Ki is increased to 206 µM. To evaluate which mechanism the kinetic data represents, global fitting 
was conducted. The datasets were fitted to the velocity equations describing a i) Ping Pong mechanism with 
a dead-end EB complex formation, ii) sequential mechanism with a dead-end EB complex formation, iii) 
sequential mechanism with dead-end EA2 complex formation, and iv) hybrid Ping Pong-ordered mechanism 
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with dead-end EB complex formation (hybrid EB).42 The hybrid Ping Pong-ordered mechanism in Figure 3 
was included in the analysis because both Ping Pong and sequential mechanisms have been observed in 
steady-state kinetic studies of the AAAHs.9,10,12 In the hybrid model28,29, the reaction can either occur through 
a Ping Pong or a sequential mechanism depending on the concentration of tryptophan. Substrate inhibition is 
caused by competitive formation of a dead-end EB (TPH•Trp) complex formed when tryptophan binds 
before BH4. Such hybrid mechanisms have also been observed in e.g. pyruvate carboxylase, glutathione 
reductase, hypoxanthine phosphoribosyltransferase, and glutathione S-transferase A.30,43- 45 In the global fit, 
the sequential mechanisms (ii and iii) resulted in identical fits, as KA was reduced to zero resulting in a 
reduction of the equations to that of a Ping Pong mechanism (i). For this reason, identical kinetic parameters 
were obtained for the three mechanisms, and the sequential mechanisms were discarded. Based on this 
analysis of the conventional non-branched mechanisms, a Ping Pong mechanism fit the total dataset best. 
The hybrid EB model, however, results in an improved global fit (p < 0.01) compared to that of a Ping Pong 
mechanism, Table 1. Fitting this model to the data results in a redundancy of K4. In the proposed hybrid 
mechanism in Figure 3, the order of pterin and substrate binding is in agreement with the majority of studies 
conducted on the AAAHs.9-11,15-17 Substrate inhibition occurs through competitive inhibition by tryptophan 
versus BH4. This yields a BH4 concentration-dependent substrate tryptophan inhibition constant which has 
similarly been observed for TH10. A hybrid Ping Pong-ordered model in which tryptophan binds before BH4 
also resulted in an improved global fit (p < 0.01) compared to that of a Ping Pong EB mechanism. This 
model was, however, discarded because of the accumulated experimental data, that evidently find that BH4 
binds as the first substrate.9-11,15-17 Biphasic data was obtained by Oka et al.10 who therefore analyzed the data 
separately for velocity data obtained at respectively higher or lower than 0.2 mM BH4. Such data might be 
explained by a hybrid Ping Pong-ordered model, which follows different mechanisms depending on substrate 
concentration. According to this proposed hybrid model, the reaction will occur through a sequential 
mechanism at high tryptophan concentrations. This correlates well with the fact that several of the AAAH 
studies which obtain a sequential mechanism were conducted with relatively high substrate concentrations 
(typically >0.5 mM range).13,14,16,17 
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Figure 1. Global fits to initial velocity measurements for chTPH1. The oxygen concentration was 500 µM in all 
measurements. (A) Initial velocities versus Trp concentration at fixed concentration of BH4. (B) Initial velocities versus BH4 
concentration at fixed concentration of Trp. The plots are fitted with eq. 3 (Hybrid Ping Pong-ordered EB mechanism). 
 
 
Figure 2. Secondary plot of apparent Ki-values obtained at different BH4 concentrations. Values obtained by fitting the v0 vs. 
Trp concentration data at fixed BH4 concentrations presented in Figure 1A with eq. 2 
 
Table 1. Kinetic parameters derived from global fits. Parameters are derived by fitting the data with a Ping Pong mechanism 
with dead-end EB and a hybrid Ping Pong-ordered mechanism with dead-end EB formation (Hybrid EB – eq. 3) to all the 
data. The model error is given by the sum of squared residuals. *: F-test, p<0.01. 
Mechanism 
Vmax V2 Km,Trp Km,BH4 Ki K3 
K4 Error 
µM min-1 min-1  µM µM µM µM-1 
Ping Pong EB 213 - 23 181 51 - - 551 
Hybrid EB 210 0.3 24 135 52 2.8 0 445* 
y = 0,4857x + 9,9257
R² = 0,9971
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Figure 3. Basic scheme for a branching mechanism of chTPH1. The scheme corresponds to a hybrid Ping Pong-ordered 
mechanism with dead-end TPH•Trp complex (EB). TPH* indicates a TPH that has undergone an irreversible change (e.g. 
formation of FeIV=O). Upper path represents a Ping Pong mechanism, and the lower path represents a sequential mechanism. 
 
Sequence and Structural Analysis of Isoform Differences – The human TPH isoforms display significantly 
different kinetic parameters, and only TPH1 is subjected to substrate inhibition.21 In this study, it was 
investigated how inhibition only apply to chTPH1. The isoforms of TPH have a sequence identity of 81 % in 
the catalytic domain, which is reflected in their similar tertiary structures. The crystal structures of the 
catalytic domains of human TPH1 (chTPH1 - pdb: 1MLW46) and human TPH2 (chTPH2 - pdb: 4V06) 
display a root mean square deviation of the Cα-atoms (RMSDCα) of 1.1 Å. The TPH structures have BH2 and 
imidazole bound in the pterin binding pocket, respectively. Crystal structures of the homologous 
phenylalanine hydroxylase have shown that binding of BH2 or BH4 do not cause structural changes.47,48 The 
two TPH structures are therefore comparable. It was found that the 19 % non-conserved residues are 
randomly distributed mainly on the surface of the protein. Within 10 Å of the active site iron, only 2 out of 
37 residues are not conserved, and these residues are distant from the binding pockets of the substrate and 
co-substrate (Supporting Information, Figure S4). As the non-conserved residues are not clustered in one 
area and are not close to the substrate or co-substrate binding sites, differences in the crystal structures 
determined by RMSDCα were analyzed. The alignment, with color-coded RMSDCα-values, in Figure 4 shows 
that a stretch of sequence, corresponding to a loop over the active site, displays relatively high RMSDCα-
values compared to the rest of the structure despite a high sequence homology. The loops span residues 117-
137 of TPH1 and 163-183 of TPH2 and are shown in Figure 5. Especially tyrosine 125/171 in the center of 
the loop displays a relatively high RMSDCα-value (5.2 Å). The corresponding loop in PAH has been found to 
reside in either an open or closed conformation depending on the active site occupancy. A closed 
conformation has only been observed in the presence of both a pterin and a substrate analogue. 49 , 50  
However, a structure of PAH with only a substrate/substrate analogue has not been determined, and it is 
therefore unknown whether the loop closure occurs solely upon binding of substrate or a combination of 
substrate and co-substrate. Compared to the closed structures of PAH, both isoforms of human TPH exist in 
open conformations. For TPH, a closed conformation has been observed in a crystal structure of chicken 
TPH 
BH4 
HO-BH4 
TPH 
TPH•BH4 
HO-Trp 
Trp TPH•BH4•Trp 
TPH*•HO-BH4 
TPH•HO-BH4•HO-Trp 
TPH* 
Trp 
TPH*•Trp 
HO-BH4 
TPH•HO-Trp 
TPH•Trp 
Ki Trp 
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TPH1 with bound substrate Trp and imidazole (pdb: 3E2T).19 From Figure 5, it is noticed that the side chain 
of the tyrosine residue is oriented towards the active site in TPH1 but is pointing away from the active site in 
TPH2. The structures of the loops and the orientation of the tyrosine residues in the crystal structures are 
assessed by electron density in the loops. The 2Fo-Fc electron density maps of the crystal structures show that 
the structures of the loops in both isoforms are well resolved (Supporting Information Figure S5 and S6).  
 
 
Figure 4. Sequence alignment of the catalytic domains of TPH1 and TPH2 (Clustal Omega 1.2.3 - * = identical, : = very 
similar, . = similar). The color scale (green is low and red is high) in the alignment shows the RMSD of the Cα-atoms 
calculated between chTPH1 (pdb: 1MLW) and chTPH2 (pdb: 4V06). The black box indicates the sequence of the active site 
loop. The numbering of the sequence is based on TPH1. 
 
 
Figure 5. Crystal structure of chTPH1 (pdb: 1MLW – open conformation) with gray surface. The active site loop of chTPH1 
is shown in green with tyrosine 125 displayed as sticks and the loop of chTPH2 (superimposed from pdb: 4V06 – open 
conformation) is shown in orange with tyrosine 171 displayed as sticks. For illustration, Trp (superimposed from pdb: 3E2T) 
and BH2 have been placed in their respective binding pockets. Trp and BH2 are shown as cyan sticks and iron is shown as 
sphere. 
ch TPH1 E G M E S V P W F P K K I S D L D H C A N R V L M Y G S E L D A D H P G F K D N V Y R K R R K Y F A D S A
ch TPH2 E E L E D V P W F P R K I S E L D K C S H R V L M Y G S E L D A D H P G F K D N V Y R Q R R K Y F V D V A
* : * . * * * * * : * * * : * * : * : : * * * * * * * * * * * * * * * * * * * * * * : * * * * * . * *
ch TPH1 M S Y K Y G D P I P K V E F T E E E I K T W G T V F R E L N K L Y P T H A C R E Y L K N L P L L S K Y C G
ch TPH2 M G Y K Y G Q P I P R V E Y T E E E T K T W G V V F R E L S K L Y P T H A C R E Y L K N F P L L T K Y C G
* . * * * * : * * * : * * : * * * * * * * * . * * * * * . * * * * * * * * * * * * * * : * * * : * * * *
ch TPH1 Y Q E D N I P Q L E D I S N F L K E R T G F S I R P V A G Y L S P R D F L S G L A F R V F H C T Q Y V R H
ch TPH2 Y R E D N V P Q L E D V S M F L K E R S G F T V R P V A G Y L S P R D F L A G L A Y R V F H C T Q Y I R H
* : * * * : * * * * * : * * * * * * : * * : : * * * * * * * * * * * * * : * * * : * * * * * * * * : * *
ch TPH1 S S D P F Y T P E P D T C H E L L G H V P L L A E P S F A Q F S Q E I G L A S L G A S E E A V Q K L A T C
ch TPH2 G S D P L Y T P E P D T C H E L L G H V P L L A D P K F A Q F S Q E I G L A S L G A S D E D V Q K L A T C
. * * * : * * * * * * * * * * * * * * * * * * * : * . * * * * * * * * * * * * * * * * : * * * * * * * *
ch TPH1 Y F F T V E F G L C K Q D G Q L R V F G A G L L S S I S E L K H V L S G H A K V K P F D P K I T C K Q E C
ch TPH2 Y F F T I E F G L C K Q E G Q L R A Y G A G L L S S I G E L K H A L S D K A C V K A F D P K T T C L Q E C
* * * * : * * * * * * * : * * * * . : * * * * * * * * . * * * * . * * . : * * * * * * * * * * * *
ch TPH1 L I T T F Q D V Y F V S E S F E D A K E K M R E F T K T I K R P F G V K Y N P Y T R S I Q I L K D
ch TPH2 L I T T F Q E A Y F V S E S F E E A K E K M R D F A K S I T R P F S V Y F N P Y T Q S I E I L K D
* * * * * * : . * * * * * * * * : * * * * * * : * : * : * . * * * . * : * * * * : * * : * * * *
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The Effect of Tyr125/171 Point Mutations on TPH Kinetics - In order to probe the importance of the loop in 
TPH, Tyr125 in chTPH1 and Tyr171 in chTPH2 were mutated to the smaller amino acid alanine or the more 
bulky amino acid tryptophan and characterized for changes. As the oligomeric state and the transition 
temperatures of the isoform mutant variants were not changed (Supporting Information, Figure S7, Table S1, 
and Table S2), the kinetic parameters can be directly compared. Apparent kinetic parameters are determined 
given that saturated concentrations of the non-varied substrate could not be obtained due to substrate 
inhibition. In agreement with Windahl et al.21, chTPH1 displays substrate inhibition, with a substrate 
inhibition constant of 165 ± 18 µM, while chTPH2 does not display substrate inhibition (Table 2, Figure 6 
panel A and C open circles). Additionally, chTPH1 displays a 10-fold higher Km,BH4 compared to chTPH2. 
The kinetic analysis shows that mutation of the tyrosine residue in the loop results in significant changes in 
the kinetic parameters of chTPH1 (Table 2 and Figure 6). Mutation to alanine results in a small reduction of 
Km,BH4, while mutation to tryptophan results in a 5-fold reduction. A change in Km,Trp is only observed for 
Y125W-chTPH1. Notably, the mutations result in a significant increase in the substrate inhibition constant, 
Ki. Mutation to alanine increases the Ki-value slightly, while mutation to tryptophan results in a greater than 
3-fold increase. The decreased substrate inhibition is clearly visualized in Figure 6 panel A. Beside the 
reduced Km,BH4 and increased Ki-values, kcat,Trp is also found to change with the mutations. Similar to the 
other kinetic parameters, kcat,Trp is slightly increased with mutation to alanine and increased 3-fold by 
mutation to tryptophan. For chTPH2, mutation from tyrosine to alanine or tryptophan results in no significant 
changes in the kinetic parameters, apart from a change in the Km,Trp. These observations correlate well with 
the different orientations of the tyrosine residue seen in the two crystal structures. In chTPH1, the tyrosine 
residue is in vicinity of the active site and influences the kinetics of the enzyme, while in chTPH2, the 
tyrosine residue point away from the active site which results in a less pronounced effect on the kinetics.  
Table 2. Kinetic parameters of chTPH1 and chTPH2 variants derived from data presented in Figure 6. Parameters are given 
with standard deviations of at least three independent experiments from at least two purification batches. *: p < 0.05, **: p < 
0.01. 
  Tryptophan   BH4 
Variant kcat (min-1) Ki (µM) Km (µM) 
 
Km (µM) kcat (min-1) 
chTPH1 108 ± 10 165 ± 18 12.7 ± 1.4  285 ± 15 145 ± 17 
Y125A-chTPH1 164 ± 10** 227 ± 21* 12.6 ± 0.5  188 ± 19** 192 ± 13* 
Y125W-chTPH1 315 ± 55** 544 ± 126** 36.7 ± 4.6**  57 ± 5** 203 ± 9* 
Loop-swap-chTPH1 178 ± 12** 189 ± 27 13.9 ± 2.7  240 ± 42 191 ± 18* 
chTPH2 258 ± 20 - 13.1 ± 1.3  26.7 ± 0.9 239 ± 12 
Y171A-chTPH2 220 ± 9 - 12.1 ± 1.3  31.1 ± 6.0 201 ± 27 
Y171W-chTPH2 315 ± 34 - 21.7 ± 1.5**  19.2 ± 3.4 274 ± 16 
Loop-swap-chTPH2 212 ± 4 497 ± 54 14.0 ± 0.7  37.6 ± 8.1 145 ± 8** 
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Loop-Swap Mutations of Non-Conserved Residues - Of the 21 residues located in the loop, only three 
residues are not conserved between the isoforms (Figure 4). To examine whether these residues contribute to 
the different orientations of the tyrosine residue, the three non-conserved residues in chTPH1 were mutated 
to the corresponding residues of the sequence of chTPH2 and vice versa. In chTPH1, His117, Ala119, and 
Asn120 were mutated to Lys, Ser, and His, respectively (referred to as loop-swap-chTPH1), while the 
opposite mutations were performed in position 163, 165, and 166 of chTPH2 (referred to as loop-swap-
chTPH2). The kinetic results of the loop-swap mutations are presented in Figure 6, and the kinetic 
parameters are summarized in Table 2. In chTPH1, the loop-swap mutations result in only modest changes in 
the kinetic parameters. Although statistically insignificant, the kinetic parameters change in the same fashion 
as observed for the Tyr125 mutations; Km,BH4 decreases, Ki increases, and kcat,Trp increases. In chTPH2, the 
loop-swap mutations similarly only introduce modest changes to the kinetic parameters. However, the loop-
swap mutations in chTPH2 result in introduction of substrate tryptophan inhibition with a Ki-value of 497 ± 
54 µM (Figure 6, panel C black circles). In chTPH1, Ki and Km,BH4 seem to be inversely related. This 
correlates with the observations in loop-swap-chTPH2 where Km,BH4 is increased with the introduced 
substrate inhibition. The conservation of the loops was analyzed (logo plot51 in Supporting Information 
Figure S8) with sequences of TPH1 and TPH2 from 61 and 63 vertebrate species, respectively. It was found 
that His117, Ala119 and Asn120 of TPH1 are 13, 100, and 97 % conserved, respectively. In TPH2, Lys163, 
Ser165, and His166 are conserved 75, 100, and 33 %, respectively. Of the residues in TPH1, Ala119 and 
Asn120 show a high degree of conservation, while for TPH2, Ser165 is highly conserved. This implies that 
these residues are important for proper loop orientation and function. 
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Figure 6. The initial rates of the chTPH1 variants (panel A and B) and of the chTPH2 variants (panel C and D) as a function 
of Trp or BH4 concentration. The oxygen concentration was 500 µM in all measurements. Each measurement is reported as 
an average with standard deviation of at least three independent experiments from at least two purification batches. The 
TPH concentration was 0.8 µM in all measurements except for Trp at 1.5 and 2.5 µM, where the concentrations were 0.24 
and 0.4 µM, respectively. 
Molecular Dynamics (MD) Simulations - MD simulations were employed to investigate the underlying 
mechanism that governs the observed substrate inhibition in TPH1. 100 ns MD simulations of chTPH1 with 
and without substrate Trp were conducted. From comparison of the trajectories, it is observed that in the 
presence of Trp, the entrance to the BH4 binding pocket becomes blocked, Figure 7. The blocking of the 
entrance is caused mainly by Tyr235. Tyr235 is in direct contact with the active site loop through Tyr125, 
which is under investigation, Figure 8A.46 Throughout the simulation of chTPH1, Tyr235 resides in a 
position very similar to the one observed in the crystal structure (average RMSDTyr235 of 1.1 Å compared to 
1MLW and 3.6 Å compared to 3E2T), Figure 8B. In the simulation of chTPH1 with Trp in the active site, 
Tyr235 moves to the position which blocks the BH4 entrance. This new position of Tyr235 is very similar to 
the one observed for the equivalent Tyr236 in the crystal structure of chicken TPH119 which has Trp bound 
(average RMSDTyr235 of 1.8 Å from 3E2T and 3.0 Å from 1MLW), Figure 8. The movement of Tyr235 
observed in the simulation of chTPH1 correlates very well with the structural information obtained from the 
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crystal structures. The importance of Tyr235 for the inhibition mechanism of TPH1 is supported by a 
mutational study, in which it was found that substrate inhibition was removed upon mutation of Tyr235 to 
alanine or leucine.52 In chTPH1, Tyr235 constitutes part of the BH4 binding pocket and is in direct contact 
with the pterin.46 Tyr125 which is under investigation in this study, π-stacks onto Tyr235 forming a T-shaped 
interaction.46 It is therefore reasonable to believe that mutation of Tyr125 has an influence on the orientation 
of Tyr235 and thereby explain the influence on the kinetic parameters, especially the substrate inhibition.  
 
 
Figure 7. Substrate Trp induced closure of the BH4 binding pocket. BH2, shown in cyan licorice, is not included in the 
simulations but have been superimposed into the structures (from pdb: 1MLW) to illustrate its binding pose. Left: snapshot 
extracted from MD simulation of chTPH1 without substrates. Right: snapshot extracted from MD simulation of chTPH1 
with bound substrate Trp. The snapshots represent the average position of Tyr235 based on the distance measurements over 
the 100 ns simulations  
 
L-Trp 
Tyr235 Tyr235 
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Figure 8. (A) The position and orientation of Tyr125, Tyr235, and BH2 in the crystal structure of chTPH1 (pdb: 1MLW). The 
active site loop is colored green and dotted lines represent distances. (B) Superposition of the crystal structure of human 
TPH1 (pdb: 1MLW), chicken TPH1 (pdb: 3E2T), snapshot from MD simulation of chTPH1 without substrate (green 
Tyr235), and snapshot from MD simulation of chTPH1 with bound Trp (orange Tyr235). The snapshots represent the 
average position of the tyrosine residues based on the distance measurements over the 100 ns simulations. 
Discussion 
The data presented here shed light on the kinetic mechanism of TPH1 and on the different kinetic properties 
which are displayed by the TPH isoforms. The kinetic mechanism of TPH has not previously been 
determined and both Ping Pong and sequential mechanisms have been observed in steady-state kinetic 
studies of the AAAHs.9-11 In this study, a hybrid Ping Pong-ordered mechanism in which the reaction can 
either occur through a Ping Pong or a sequential mechanism depending on the concentration of tryptophan is 
observed. The substrate binding order is BH4 followed by tryptophan and substrate inhibition occurs through 
competitive inhibition of tryptophan versus BH4. This order of substrate binding is in agreement with the 
majority of studies conducted on the AAAHs.9-12,15-17 This model might explain the contradicting results 
obtained for the AAAHs because very different substrate concentrations are used in these studies.  
In this study, wild-type chTPH1 and chTPH2 displayed identical Km,Trp-values but a 10-fold difference in 
Km,BH4-values. Furthermore, a ~2-fold greater kcat,Trp was observed for chTPH2 compared to chTPH1 and 
only chTPH1 displayed substrate inhibition. These kinetic parameters correlate well with previous 
observation21,25,53 although slight variations are seen in some cases. This might be due to that data are based 
on TPH from different organisms. TPH2 has similarly been reported not to be subject of substrate 
inhibition1,22, 54  but has also been found to display inhibition, however, with relatively high inhibition 
constants (418 - 970 µM)20, 55. Substrate inhibition is an important regulatory mechanism observed in a 
variety of enzymes.56 Amino acid substrate inhibition has been observed in both full-length human TPH1 
and rat TH.57,58 Deletion mutagenesis has shown that substrate inhibition is retained to upon deletion of 
either the regulatory or tetramerization domain of TPH and TH.23,58 This suggests that the observed substrate 
inhibition in full-length TPH and TH only involves the catalytic domain, which implies that the results 
obtained in this study can be applied to the full-length enzyme. The sequence and structural analyses of the 
Tyr235 Tyr125 
BH2 
3.8 Å 
3.6 Å 
Tyr235 (1MLW) 
Tyr236 (3E2T) 
A B 
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two isoforms revealed that the biggest difference between the crystal structures is the tyrosine residue in the 
active site loop. Mutation of this residue resulted in significant changes in the kinetic parameters of only 
chTPH1. This implies that this residue has a functional importance in TPH1. The importance of this loop and 
in particular this residue is supported by findings in PAH and TH where the corresponding residues Tyr138 
and Phe184 have been found to be important for proper enzymatic function.59,60  
Crystal structures of TPH and PAH have clearly revealed the presence of an open and a closed conformation. 
For PAH, closed conformations have only been observed when both a pterin and a substrate analogue are 
bound.49,50  A closed conformation has also been observed for chicken TPH1 with bound tryptophan and 
imidazole.19 Imidazole is bound in the BH4 binding pocket, which might mimic binding of co-substrate.  
However, a structure of TPH or PAH with only a substrate/substrate analogue has not been determined, and 
it is therefore unknown whether the loop closure occurs solely upon binding of substrate or a combination of 
substrate and co-substrate. The role of the loop closing mechanism is poorly understood. For PAH, it has 
been suggested that the closing mechanism might protect the co-substrate to enable a high degree of coupling 
efficiency.59 Similarly, the loop in TH has been proposed to exclude water from the active site to avoid 
reaction of the water with the hydroxylating intermediate before hydroxylation of substrate can occur.48,60,61 
A similar functional importance of the loop in TPH is supported by the very high sequence conservation 
among vertebrate species observed for both TPH isoforms. From the MD simulations, it is observed that Trp 
binding in chTPH1 results in a blocking of the BH4 binding pocket. The Trp-induced blocking mechanism 
occurs through Tyr235 which moves from a BH4 binding position to a position in the opening of the BH4 
binding pocket. This observation compliments the kinetic model in which a dead-end complex is formed 
when Trp binds before BH4. The influence of Tyr235 on the substrate inhibition mechanism is also supported 
by the results of Jiang et al. where mutations of Tyr235 to alanine or leucine were found to remove substrate 
inhibition.52 Tyr235 is in direct contact with the active site loop through Tyr125.46 The mutations of Tyr125 
will therefore most likely have an influence on the orientation of Tyr235, and thereby explain the influence 
on the kinetic parameters, especially the substrate inhibition. These results strongly suggest that the 
inhibition mechanism, which is only observed for chTPH1, can be traced to the loop lining the active site. 
The induced substrate inhibition observed in loop-swap-chTPH2 suggests that the three mutations change the 
orientation of the loop to an orientation approaching the one observed in chTPH1.  
Besides chTPH1, substrate inhibition is also observed in TH. For TH, substrate inhibition is observed at 
tyrosine concentrations higher than 50 µM62. The tyrosine concentration in the brain has been found to vary 
as much as a factor of two.63 Substrate inhibition of TH has been proposed to explain the lack of L-DOPA 
concentration fluctuations as a consequence of increase Tyr concentration upon food intake.56 Trp 
concentrations are around 60 µM in the blood 64 which is close to the Trp concentration at which the 
maximum velocity of TPH1 is achieved in this study. This suggests that substrate inhibition could play a role 
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in the TPH1 regulation in vivo. It is possible that a corresponding mechanism observed for TH is ensuring 
that the production of 5-HT does not rise to high levels in the peripheral tissues, which is associated with 
several diseases.65 The concentration of tryptophan in the brain is in the range of 25-35 µM66 which is close 
to the observed Km,Trp of chTPH2. The velocities of 5-HTP production and in turn serotonin production are, 
therefore, very sensitive to changes in brain Trp concentration.66, 67 This might explain the lack of substrate 
inhibition observed in TPH2, as rapid responses are desirable in the brain. It could be speculated that 
different regulatory mechanisms of the two isoforms have evolved to accommodate the diverse need for 
serotonin biosynthesis in different tissues. 
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